DK0457295T3 - Anvendelse af en modulator af proteinphosphorylering ved behandling af amyloidose knyttet til Alzheimers sygdom - Google Patents

Anvendelse af en modulator af proteinphosphorylering ved behandling af amyloidose knyttet til Alzheimers sygdom

Info

Publication number
DK0457295T3
DK0457295T3 DK91107844.2T DK91107844T DK0457295T3 DK 0457295 T3 DK0457295 T3 DK 0457295T3 DK 91107844 T DK91107844 T DK 91107844T DK 0457295 T3 DK0457295 T3 DK 0457295T3
Authority
DK
Denmark
Prior art keywords
modulator
alzheimer
disease
treatment
amyloidosis associated
Prior art date
Application number
DK91107844.2T
Other languages
Danish (da)
English (en)
Inventor
Joseph D Buxbaum
Samuel E Gandy
Paul Greengard
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24088213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0457295(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of DK0457295T3 publication Critical patent/DK0457295T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Radiation-Therapy Devices (AREA)
  • Enzymes And Modification Thereof (AREA)
DK91107844.2T 1990-05-16 1991-05-15 Anvendelse af en modulator af proteinphosphorylering ved behandling af amyloidose knyttet til Alzheimers sygdom DK0457295T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52420290A 1990-05-16 1990-05-16

Publications (1)

Publication Number Publication Date
DK0457295T3 true DK0457295T3 (da) 1997-04-28

Family

ID=24088213

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91107844.2T DK0457295T3 (da) 1990-05-16 1991-05-15 Anvendelse af en modulator af proteinphosphorylering ved behandling af amyloidose knyttet til Alzheimers sygdom

Country Status (8)

Country Link
EP (1) EP0457295B1 (fr)
JP (1) JPH0725786A (fr)
AT (1) ATE151287T1 (fr)
CA (1) CA2042668C (fr)
DE (1) DE69125523T2 (fr)
DK (1) DK0457295T3 (fr)
ES (1) ES2102986T3 (fr)
GR (1) GR3024032T3 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
EP0544942A1 (fr) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nouveaux outils pour le diagnostic et le traitement de la maladie d'Alzheimer
DK0618968T3 (da) * 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
EP0551200A1 (fr) * 1992-01-07 1993-07-14 National University Of Singapore Protéine phosphatase inhibiteur pour l'utilisation en thérapeutique
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
JP2893029B2 (ja) * 1992-08-10 1999-05-17 旭化成工業株式会社 心臓保護剤
JPH0680569A (ja) * 1992-09-03 1994-03-22 Asahi Chem Ind Co Ltd 血小板凝集阻害剤
WO1994009370A1 (fr) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Liberation d'un precurseur amyloide de la maladie d'alzheimer, stimulee par activation des recepteurs d'acetylcholine muscarinique
US5962463A (en) * 1992-10-09 1999-10-05 Massachusetts Institute Of Technology Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein
WO1994022437A2 (fr) * 1993-03-29 1994-10-13 Queen's University At Kingston Procede de traitement de l'amyloïdose
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
EP0701441A1 (fr) * 1993-06-01 1996-03-20 Cortex Pharmaceuticals, Inc. Inhibiteurs de phosphatase alcaline et acide utilises dans le traitement de troubles neurologiques
IL110289A (en) * 1993-08-06 1998-01-04 Policlinico San Matteo Istitut Pharmaceutical preparations containing 4-iodo-4-deoxydoxorubicin for the treatment of amyloidosis
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US6083920A (en) * 1995-12-21 2000-07-04 Ayurcore, Inc. Compositions for modulating intracellular inositol trisphosphate concentration
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
WO1999016457A2 (fr) * 1997-10-01 1999-04-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvelle composition pour traiter, prevenir et/ou retarder la mort cellulaire ischemique
WO2000003746A2 (fr) * 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Remise a niveau de la synthase dl'oxyde nitrique des cellules endotheliales de type iii par des agents venant disloquer l'organisation cytosquelettique de l'actine
WO2000037072A1 (fr) * 1998-12-22 2000-06-29 Alcon Laboratories, Inc. Utilisation d'inhibiteurs de synthese de gag pour le traitement de l'opacite corneenne
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
DE10352450A1 (de) * 2003-11-07 2005-06-23 Ruprecht-Karls-Universität Heidelberg Neues Mittel zur prophylaktischen und/oder therapeutischen Behandlung von Morbus Alzheimer
CN101084204B (zh) 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
BRPI0519243A2 (pt) 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
MX2008008213A (es) 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
SI2004155T1 (en) 2006-03-29 2018-05-31 Wista Laboratories Ltd. Inhibitors of protein aggregation
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
AU2016321298A1 (en) * 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
CA3084139C (fr) * 2017-11-15 2023-02-28 Korea Research Institute Of Bioscience And Biotechnology Composition destinee a prevenir ou a traiter des maladies neurodegeneratives, contenant un compose a base de diterpene
JP7037814B2 (ja) * 2018-03-28 2022-03-17 国立大学法人山口大学 ホルボールエステルを有効成分とする軸索の伸展剤
US20250032530A1 (en) * 2021-10-26 2025-01-30 University Of South Florida Use of auranofin as an inhibitor of atypical protein kinase c for treatment of neurodegenerative disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085913B2 (ja) * 1985-09-12 1996-01-24 ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド 治療用ソマトスタチン同族体

Also Published As

Publication number Publication date
DE69125523D1 (de) 1997-05-15
CA2042668C (fr) 2002-12-03
CA2042668A1 (fr) 1991-11-17
EP0457295A3 (en) 1992-08-05
EP0457295A2 (fr) 1991-11-21
EP0457295B1 (fr) 1997-04-09
GR3024032T3 (en) 1997-10-31
ATE151287T1 (de) 1997-04-15
JPH0725786A (ja) 1995-01-27
ES2102986T3 (es) 1997-08-16
DE69125523T2 (de) 1997-08-14

Similar Documents

Publication Publication Date Title
DK0457295T3 (da) Anvendelse af en modulator af proteinphosphorylering ved behandling af amyloidose knyttet til Alzheimers sygdom
DK549189D0 (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge
EE05492B1 (et) Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral
FI962557A0 (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
FR2642855B1 (fr) Lentille optique pour la correction de l'astigmatisme
AU7197387A (en) Novel styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors, pharmaceutical compositions and methods of use therefor
DE69502539D1 (de) Sarpogrelat enthaltende opthalmologische Zubereitungen zur Senkung des intraokularen Druckes
DE69841267D1 (de) Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom
ATE350051T1 (de) Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten
ATE229336T1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
FR2659204B3 (fr) Applique-cire pour la depilation.
MX9201825A (es) Composicion farmaceutica que contiene calcitonina.
FR2614227B1 (fr) Meuleuse perfectionnee pour verres ophtalmiques.
DK131188A (da) 3-(2-halogenalkyl)-1,4-oxathiiner og 2(2-halogenalkyl)-1,4-dithiiner, samt farmaceutiske praeparater indeholdende disse til behandling af leukaemi og tumorer
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
NO912823L (no) Fremgangsmaate for fremstilling av klasse ii-proteinet av neisseria meningitidis samt vaksiner som inneholder dette.
NO953072L (no) Anvendelse av inhibitorer av ornitinaminotransferase for fremstilling av et medikament for behandling av Alzheimers sykdom
IE873083L (en) Tecombinant alzheimer's amyloid protein.
IT8222416A0 (it) Procedimento per l'estrazione del cromo e delle proteine dagli scarti delle pelli conciate al cromo.
FR2661831B1 (fr) Formules pharmaceutiques pour le traitement des maladies vasculaires peripheriques.
NO930083D0 (no) Sammensetning for behandling av alzheimers sykdom og fremgangsmaate for fremstilling
BE883088A (fr) 5-(2-((3-(1,3-benzodioxole-5-yl)-1-methylpropyl) amino) - 1-hydroxyethyl) -2-methoxybenzamide utile notamment dans le traitement de l'hypertension